ACME UNITED CORP - 10-Q Summary (Period Ended June 30, 1999)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1999, and the six months ended on that date. ACME United Corporation is a manufacturer and distributor of consumer products. A significant event during this period was the sale of its medical business division on March 22, 1999, which has been classified as discontinued operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1999 | Six Months Ended June 30, 1998 |
|---|---|---|
| Net Sales (Continuing) | $17,383,000 | $18,744,000 |
| Net Income | $1,882,000 | $26,000 |
| Income from Continuing Ops | $(417,000) | $(506,000) |
| Gross Margin (Continuing) | 22.7% | 23.3% |
| Cash and Equivalents | $33,000 | $62,000 |
| Total Debt | $10,193,000 | $15,326,000 |
| Working Capital | $284,000 | $3,616,000 |
| Current Ratio | 1.01 | 1.20 |
Material Changes vs. Prior Period
- Discontinued Operations: The company sold its medical division for $8.156 million, realizing a gain of $2.101 million. This gain was the primary driver of the net income for the six-month period, masking a loss from continuing operations.
- Revenue Decline: Net sales from continuing operations decreased 7.3% year-over-year. Management attributes this to the sale of the medical business and a slowdown in international sales (down 18%), particularly in the UK.
- Debt Reduction: Total debt decreased by $5.133 million, largely due to using proceeds from the medical division sale to pay down $6.8 million in outstanding debt.
- Liquidity Tightening: Working capital dropped significantly from $3.6 million to $284,000, and the current ratio declined from 1.20 to 1.01. Cash flow from operating activities was negative ($2.561 million used), while investing activities provided $7.814 million due to the asset sale.
- Margin Improvement: Despite lower sales, gross margins for continuing operations improved slightly due to product sourcing alternatives and cost savings from re-sourcing products acquired from Esselte Canada.
Guidance, Outlook, Risks, and Contingencies
- Debt Refinancing Risk: Approximately $8.6 million of debt matures by April 30, 2000, and is currently classified as current. The company is negotiating to refinance these arrangements. Management states that without adequate financing, the company would be unable to fund obligations, though they believe refinancing will be successful.
- Covenants: The company is currently in compliance with debt covenants regarding tangible net worth and debt service coverage ratios.
- Year 2000 Compliance: The company is completing Y2K modifications, with a new financial system being implemented in Germany. Estimated future costs range from $100,000 to $125,000.
- Legal Contingencies: The company is involved in environmental matters and lawsuits regarding latex products. Management believes these will not have a material adverse impact.
- Outlook: Management expects to continue consolidating product sourcing from Asia to improve margins. Capital expenditures for the next 12 months are expected to be under $250,000.
Investor Verification Checklist
- Refinancing Status: Verify the outcome of negotiations to extend the maturity of the $8.6 million debt obligation beyond December 31, 2000.
- Continuing Operations Viability: Analyze the loss from continuing operations ($417,000 for six months) excluding the one-time gain from the medical division sale.
- Liquidity Position: Monitor the current ratio (1.01) and working capital ($284,000) for signs of further tightening.
- International Exposure: Assess the impact of the 18% decline in international sales and currency fluctuations on future revenue.
- Y2K Costs: Confirm actual costs incurred for Year 2000 compliance against the estimated $100,000-$125,000 range.